Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

ARTV

Artiva Biotherapeutics Inc

Jun 18 • 04:00PM ET

9.82

-0.12 -1.21 %

Healthcare • Biotechnology • USA • Micro • NASD

Peers: ALLO DTIL PRME BBOT RGNX KYTX VYGR MGTX SLDB CRMD

| Held by: VTI SURI VXF DFMC IWC DFAS DCOR

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-3.55	Insider Own	37.30%	Shs Outstand	24.72M	Perf Week	22.75%
Market Cap	242.75M	Forward P/E	-	EPS next Y	-2.91	Insider Trans	102.49%	Shs Float	15.50M	Perf Month	14.85%
Enterprise Value	166.23M	PEG	-	EPS next Q	-0.63	Inst Own	91.90%	Short Float	6.62%	Perf Quarter	77.90%
Income	-87.07M	P/S	-	EPS this Y	22.26%	Inst Trans	-0.49%	Short Ratio	2.07	Perf Half Y	115.82%
Sales	0.00M	P/B	2.76	EPS next Y	-9.17%	ROA	-58.59%	Short Interest	1.03M	Perf YTD	128.90%
Book/sh	3.55	P/C	2.80	EPS next 5Y	3.82%	ROE	-67.86%	52W High	14.53 -32.42%	Perf Year	484.52%
Cash/sh	3.51	P/FCF	-	EPS past 3/5Y	-12.33% -27.38%	ROIC	-91.58%	52W Low	1.47 568.03%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	11.45% 10.87%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-18.99%	Oper. Margin	-	ATR (14)	0.97	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	8.16	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	60.52	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	8.16	EPS Q/Q	-14.20%	SMA20	23.98%	Beta	2.05	Target Price	35.80
Payout	-	Debt/Eq	0.12	Sales Q/Q	-	SMA50	5.64%	Rel Volume	3.53	Prev Close	9.94
Employees	104	LT Debt/Eq	0.08	Earnings	May 08 BMO	SMA200	78.91%	Avg Volume	494.75K	Price	9.82
IPO	Jul 19, 2024	Option/Short	No / Yes	EPS/Sales Surpr.	-9.20% -	Trades		Volume	1,745,234	Change	-1.21%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-11-25	Resumed	H.C. Wainwright	Buy	$12
Dec-30-24	Initiated	H.C. Wainwright	Buy	$20
Aug-13-24	Initiated	Wedbush	Outperform	$18
Aug-13-24	Initiated	TD Cowen	Buy
Aug-13-24	Initiated	Needham	Buy	$23
Aug-13-24	Initiated	Jefferies	Buy	$21
Aug-13-24	Initiated	Cantor Fitzgerald	Overweight	$23

Jun-08-26 06:30AM	Artiva Biotherapeutics Highlights AlloNK Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today (GlobeNewswire)
May-29-26 09:00AM	The $13 Million Company Teaching the Immune System to Hunt Cancer (PR Newswire)
May-28-26 08:00AM	Artiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conference (GlobeNewswire)
May-19-26 04:05PM	Artiva Biotherapeutics Announces Multiple AlloNK Data Presentations at EULAR 2026 Congress, Including Late-Breaking Oral Presentation Highlighting Clinical Efficacy Comparable to Autologous CAR T-Cell Therapy in Rheumatologic Diseases (GlobeNewswire) -7.27% -8.30%
08:00AM	Artiva Biotherapeutics Appoints Veteran Biotech Executive and Drug Developer Diego Miralles, M.D., as President and Head of Research and Development (GlobeNewswire)
06:52AM	Loading…
May-08-26 06:52AM	Artiva Biotherapeutics Announces Pricing of $300 Million Underwritten Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) -13.02%
06:31AM	Artiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights (GlobeNewswire)
06:30AM	Artiva Announces Positive Initial Clinical Data with AlloNK Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial in Rheumatoid Arthritis in 2026 (GlobeNewswire)
Apr-08-26 08:00AM	Artiva Biotherapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference (GlobeNewswire) -7.20%
Mar-10-26 04:05PM	Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights (GlobeNewswire) +6.48% +17.27%
Mar-04-26 03:13PM	Artiva Biotherapeutics Pivots to Rheumatoid Arthritis at TD Cowen, Teases 2026 RA Data Update (MarketBeat)
Feb-25-26 08:00AM	Artiva Biotherapeutics to Participate in the TD Cowen 46th Annual Health Care Conference (GlobeNewswire)
Feb-24-26 08:00AM	Artiva Biotherapeutics Announces Appointment of Thad Huston as Chief Financial Officer and Award of Inducement Grant (GlobeNewswire)
Feb-19-26 08:21AM	AtaiBeckley names Michael Faerm as finance chief (Proactive) +9.16%
08:00AM	Artiva Biotherapeutics Announces Appointment of Elaine Sorg to Board of Directors (GlobeNewswire)
08:00AM	Loading…
Jan-21-26 08:00AM	Artiva Biotherapeutics Announces Upcoming Presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (Tandem Meetings) Highlighting Cost-Effectiveness of AlloNK in a Community Rheumatology Practice and Continued Durability of AlloNK in NHL (GlobeNewswire)
Dec-14-25 06:05AM	Wedbush Predicts Up to ~600% Jump for These 2 Strong Buy Stocks (TipRanks)
Nov-12-25 07:20AM	Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK in Autoimmune Disease (GlobeNewswire) +10.86%
07:00AM	Artiva Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
Nov-03-25 04:05PM	Artiva Biotherapeutics to Host Virtual Event Discussing Initial Safety and Translational Data in up to 32 Patients with Autoimmune Disease Treated with AlloNK (GlobeNewswire) -9.59%
Oct-30-25 04:17PM	Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in November (GlobeNewswire) -10.25% +5.84%
Oct-22-25 07:41AM	Artiva Biotherapeutics Prioritizes Refractory Rheumatoid Arthritis as Lead Indication for AlloNK (AB-101) (Insider Monkey)
Oct-16-25 04:05PM	Artiva Biotherapeutics Announces Refractory Rheumatoid Arthritis as Lead Indication, Upcoming Data Releases, and Corporate Update (GlobeNewswire) -7.97% +116.97%
Aug-25-25 04:05PM	Artiva Biotherapeutics to Participate in the Cantor Global Healthcare Conference 2025 (GlobeNewswire)
Aug-06-25 04:05PM	Artiva Biotherapeutics Reports Second Quarter 2025 Financial Results, Recent Business Highlights (GlobeNewswire) -6.82% -8.01%
May-28-25 04:05PM	Artiva Biotherapeutics to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire) +6.77%
May-13-25 04:05PM	Artiva Biotherapeutics Announces Longer-term Phase 1/2 Data Demonstrating Prolonged Durability for AlloNK in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting (GlobeNewswire) -11.71%
May-08-25 08:00AM	Artiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business Highlights (GlobeNewswire)
Apr-28-25 04:35PM	Artiva Biotherapeutics to Present Longer-term Phase 1/2 Data for AlloNK in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting (GlobeNewswire)
Apr-08-25 04:05PM	Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer (GlobeNewswire) -41.99%
04:05PM	Loading…
Mar-31-25 04:05PM	Artiva Biotherapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire) -5.06%
Mar-24-25 04:05PM	Artiva Biotherapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights (GlobeNewswire) -8.43%
Feb-20-25 04:05PM	Artiva Biotherapeutics to Participate in the TD Cowen 45th Annual Health Care Conference (GlobeNewswire) -5.72%
Jan-29-25 04:05PM	Artiva Biotherapeutics Expands Board of Directors with Appointment of Dan Baker, M.D. (GlobeNewswire)
Nov-12-24 04:05PM	Artiva Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire) -10.48%
Nov-11-24 04:05PM	Artiva Biotherapeutics to Participate in the Jefferies London Healthcare Conference (GlobeNewswire)
Oct-22-24 04:05PM	Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors (GlobeNewswire) +7.82%
Sep-10-24 04:05PM	Artiva Biotherapeutics to Participate in the 2024 Cantor Fitzgerald Global Healthcare Conference (GlobeNewswire)
Aug-29-24 04:05PM	Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Jul-18-24 07:08PM	Artiva Biotherapeutics Announces Pricing of Upsized $167.0 Million Initial Public Offering (GlobeNewswire)

Artiva Biotherapeutics, Inc. operates as a biotechnology company for the treatment of hematologic cancers. It offers NK cell therapies for cancer. The company was founded by Thomas J. Farrell in 2019 and is headquartered in San Diego, CA.

CEODr. Fred Aslan M.D.

President and Head of Research & DevelopmentDr. Gines Diego Miralles M.D.

J.D.Ms. Jennifer Kinsbruner Bush Esq.

Chief Technical Operations OfficerMr. Christopher P. Horan

Co-Founder & Strategic AdvisorDr. Peter Flynn Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
RA CAPITAL MANAGEMENT, L.P.	Director	Jun 12 '26	Buy	8.57	391,019	3,351,033	16,622,736	Jun 16 06:08 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Jun 16 '26	Buy	8.89	124,893	1,110,299	16,763,043	Jun 16 06:08 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Jun 15 '26	Buy	8.99	15,414	138,572	16,638,150	Jun 16 06:08 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Jun 11 '26	Buy	7.91	548,580	4,339,268	16,231,717	Jun 11 07:36 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Jun 09 '26	Buy	6.91	479,039	3,310,159	15,683,034	Jun 11 07:36 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Jun 10 '26	Buy	7.00	103	721	15,683,137	Jun 11 07:36 PM
GC Corp.	10% Owner	May 11 '26	Buy	11.52	1,085,069	12,499,995	4,391,969	May 28 04:34 PM
GC Corp.	10% Owner	May 11 '26	Buy	11.52	347,222	3,999,997	1,607,734	May 28 04:34 PM
Raymon Heather	SVP, Research and Development	May 19 '26	Sale	9.01	3,095	27,879	148,228	May 19 09:52 PM
Horan Christopher	Chief Tech Operations Officer	May 19 '26	Sale	9.01	7,002	63,073	293,450	May 19 09:52 PM
Bush Jennifer	COO, CLO, Compliance Officer	May 19 '26	Sale	9.01	8,790	79,179	337,920	May 19 09:51 PM
Banerjee Subhashis	Chief Medical Officer	May 19 '26	Sale	9.01	7,037	63,386	144,963	May 19 09:50 PM
Aslan Fred	Chief Executive Officer	May 19 '26	Sale	9.01	27,116	244,253	1,535,082	May 19 09:50 PM
Heather Raymon	Officer	May 18 '26	Proposed Sale	9.22	3,500	32,270		May 18 07:54 PM
Christopher P. Horan	Officer	May 18 '26	Proposed Sale	9.22	7,500	69,150		May 18 07:53 PM
Jennifer Bush	Officer	May 18 '26	Proposed Sale	9.22	9,000	82,980		May 18 07:51 PM
Subhashis Banerjee	Officer	May 18 '26	Proposed Sale	9.22	7,000	64,540		May 18 07:49 PM
Fred Aslan, M.D.	Officer	May 18 '26	Proposed Sale	9.22	28,000	258,160		May 18 07:48 PM
RA CAPITAL MANAGEMENT, L.P.	Director	May 11 '26	Buy	11.52	6,510,416	74,999,992	15,203,995	May 13 05:45 PM
Aslan Fred	President and CEO	Dec 15 '25	Sale	6.00	3,187	19,122	1,209,948	Dec 15 09:19 PM
FRED ASLAN	Director	Dec 15 '25	Proposed Sale	3.30	12,749	42,072		Dec 15 04:18 PM
Aslan Fred	President and CEO	Nov 17 '25	Sale	3.38	6,375	21,522	343,999	Nov 17 08:37 PM
FRED ASLAN	Director	Nov 17 '25	Proposed Sale	3.25	6,375	20,719		Nov 17 04:29 PM
Aslan Fred	President and CEO	Oct 17 '25	Sale	6.00	25,500	153,000	356,721	Oct 17 08:44 PM
FRED ASLAN	Director	Oct 17 '25	Proposed Sale	2.77	25,500	70,635		Oct 17 04:17 PM
Aslan Fred	President and CEO	Aug 15 '25	Sale	2.73	25,500	69,579	386,693	Aug 18 08:15 PM
FRED ASLAN	Director	Aug 15 '25	Proposed Sale	2.70	25,500	68,850		Aug 15 04:24 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ARTV

Artiva Biotherapeutics Inc

Upgrade your Finviz experience